Biomarkers and translational research and precision medicine

36P - Endocrine implications in male breast cancer in Bulgaria

Authors
  • Assia A. Konsoulova-Kirova (Varna, Bulgaria)
  • Kalin Kalchev (Varna, Bulgaria)
  • Angel Yordanov (Pleven, Bulgaria)
  • Samar El Shemeri (Varna, Bulgaria)
  • Strahil A. Strashilov (Pleven, Bulgaria)
  • Svilen I. Maslyankov (Sofia, Bulgaria)
  • Kostadin G. Angelov (Sofia, Bulgaria)
  • Dessislava Kostova-Lefterova (Pleven, Bulgaria)
  • Yaroslava Marincheva (Burgas, Bulgaria)
  • Mariela B. Vasileva (Sofia, Bulgaria)
Speakers
  • Assia A. Konsoulova-Kirova (Varna, Bulgaria)

Previous ePoster
35P - Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity

Next ePosters
38P - Defining the physiological miRNA landscape in nipple aspirate fluid
40P - WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells
42P_PR - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study
43P - CIP2A as a novel target to combat basal like breast cancer
46P - BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy
51P - Higher ER load is not associated with better outcome in stage I-III breast cancer
52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients